Marufa Mustari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marufa Mustari has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Shahjada Selim
Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
9 shared publications - Abul Bashar Mohammad Kamrul Hasan
Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh
5 shared publications - Mohammad Abdul Hannan
Department of Endocrinology, North East Medical College & Hospital, Sylhet, 3100, Bangladesh
4 shared publications - Mohammad Motiur Rahman
Department of Medicine, Rajshahi Medical College Hospital, Rajshahi, Bangladesh
4 shared publications - Muhammad Shah Alam
Department of Medicine, Army Medical College Cumilla, Cumilla, Bangladesh
4 shared publications - Abu Jar Gaffar
Department of Pathology, Naogaon Medical College, Naogaon, Bangladesh
3 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-16
Real-World Effectiveness and Safety of Imeglimin in Type 2 Diabetes: Prospective Multi-Center Study in Bangladesh
Background: This study assessed the real-world effectiveness and safety of imeglimin among Bangladeshi patients with type 2 diabetes mellitus (T2DM). Methods: This prospective, multi-center observational study was conducted across 15 specialized diabetes care centers in Bangladesh from January 2024 to December 2024. Adults with uncontrolled T2DM (HbA1c > 7%) prescribed imeglimin (500– 2000 mg daily) either as monotherapy or combination therapy were enrolled. A total of 898 subjects were assessed at baseline, 3 months, and 6 months. Primary outcomes were changes in HbA1c, fasting plasma glucose (FPG), and postprandial plasma glucose (PPPG). Secondary outcomes included body mass index (BMI), blood pressure, lipids, and safety parameters. Results: The mean age was 46.2 ± 13.1 (SD) years, with 67% being female. Baseline HbA1c decreased from 9.2± 1.4% to 7.1± 1.0% at 6 months (mean change: − 2.1%, p< 0.001). FPG reduced from 9.37± 2.53 to 7.28± 4.63 mmol/L (p< 0.001) and PPPG from 14.36± 3.29 to 8.95± 1.76 mmol/L (p< 0.001). BMI decreased from 28.1± 4.2 to 25.6± 3.6 kg/m2 (p< 0.001). Significant improvements occurred in blood pressure, lipids, and renal parameters. Adverse events were mild; 3.6% reported ≥ 1 event (gastrointestinal 2.4%, dehydration 1.3%). No serious adverse events occurred. Conclusion: Imeglimin demonstrated substantial glycemic improvements and favorable safety in real-world Bangladeshi patients with poor glycemic control.
- 1 February 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-16
Open AccessReal-World Effectiveness and Safety of Imeglimin in Type 2 Diabetes: Prospective Multi-Center Study in Bangladesh
Background: This study assessed the real-world effectiveness and safety of imeglimin among Bangladeshi patients with type 2 diabetes mellitus (T2DM). Methods: This prospective, multi-center observational study was conducted across 15 specialized diabetes care centers in Bangladesh from January 2024 to December 2024. Adults with uncontrolled T2DM (HbA1c > 7%) prescribed imeglimin (500– 2000 mg daily) either as monotherapy or combination therapy were enrolled. A total of 898 subjects were assessed at baseline, 3 months, and 6 months. Primary outcomes were changes in HbA1c, fasting plasma glucose (FPG), and postprandial plasma glucose (PPPG). Secondary outcomes included body mass index (BMI), blood pressure, lipids, and safety parameters. Results: The mean age was 46.2 ± 13.1 (SD) years, with 67% being female. Baseline HbA1c decreased from 9.2± 1.4% to 7.1± 1.0% at 6 months (mean change: − 2.1%, p< 0.001). FPG reduced from 9.37± 2.53 to 7.28± 4.63 mmol/L (p< 0.001) and PPPG from 14.36± 3.29 to 8.95± 1.76 mmol/L (p< 0.001). BMI decreased from 28.1± 4.2 to 25.6± 3.6 kg/m2 (p< 0.001). Significant improvements occurred in blood pressure, lipids, and renal parameters. Adverse events were mild; 3.6% reported ≥ 1 event (gastrointestinal 2.4%, dehydration 1.3%). No serious adverse events occurred. Conclusion: Imeglimin demonstrated substantial glycemic improvements and favorable safety in real-world Bangladeshi patients with poor glycemic control.
- Open Access
- 6 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e93912
Approach to Diagnosis and Management of Polycystic Ovary Syndrome in Bangladesh: A Nationwide Cross-Sectional Survey of Physicians
Background: Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder among women of reproductive age. This nationwide cross-sectional study aimed to assess physicians' diagnostic and management practices for PCOS in Bangladesh, with a particular focus on adherence to established guidelines. Methods: This nationwide cross-sectional survey was conducted between April and October 2024 among general practitioners and specialists using a semi-structured questionnaire. Information on demographic characteristics, diagnostic and therapeutic practice patterns, and use of clinical guidelines was collected. Descriptive statistical methods were applied. Results: Among the 643 practicing physicians, 553 (86%) were specialists in Gynecology and Obstetrics, followed by general practitioners (7.8%), endocrinologists (4%), and others. The European Society for Human Reproduction and Embryology (ESHRE) was the most commonly followed guideline (37%), along with other evidence-based guidelines. Infertility, irregular menstrual cycles, and hirsutism were frequent presenting symptoms, while infertility, type 2 diabetes, and obesity were identified as major long-term risks. Lifestyle modifications (515, 80%) and metformin (466, 72.5%) were the most common treatment strategies. Overall, 573 (89.1%, 95% CI: 86.7%-91.5%) physicians reported applying at least one recognized guideline. However, advising follow-up varied, with only 180 (52%) recommending follow-ups within 12 weeks. Furthermore, 465 (74.6%) participants who wanted a referral system supported the establishment of a structured referral system, with endocrinologists and gynecologists as the preferred specialists. Conclusion: While most physicians reported familiarity with international guidelines, variations in adherence and follow-up practices were observed. The development of a unified, context-specific national guideline is recommended to strengthen standardization of care and improve patient outcomes in Bangladesh.
- 6 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e93912
Open AccessApproach to Diagnosis and Management of Polycystic Ovary Syndrome in Bangladesh: A Nationwide Cross-Sectional Survey of Physicians
Background: Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder among women of reproductive age. This nationwide cross-sectional study aimed to assess physicians' diagnostic and management practices for PCOS in Bangladesh, with a particular focus on adherence to established guidelines. Methods: This nationwide cross-sectional survey was conducted between April and October 2024 among general practitioners and specialists using a semi-structured questionnaire. Information on demographic characteristics, diagnostic and therapeutic practice patterns, and use of clinical guidelines was collected. Descriptive statistical methods were applied. Results: Among the 643 practicing physicians, 553 (86%) were specialists in Gynecology and Obstetrics, followed by general practitioners (7.8%), endocrinologists (4%), and others. The European Society for Human Reproduction and Embryology (ESHRE) was the most commonly followed guideline (37%), along with other evidence-based guidelines. Infertility, irregular menstrual cycles, and hirsutism were frequent presenting symptoms, while infertility, type 2 diabetes, and obesity were identified as major long-term risks. Lifestyle modifications (515, 80%) and metformin (466, 72.5%) were the most common treatment strategies. Overall, 573 (89.1%, 95% CI: 86.7%-91.5%) physicians reported applying at least one recognized guideline. However, advising follow-up varied, with only 180 (52%) recommending follow-ups within 12 weeks. Furthermore, 465 (74.6%) participants who wanted a referral system supported the establishment of a structured referral system, with endocrinologists and gynecologists as the preferred specialists. Conclusion: While most physicians reported familiarity with international guidelines, variations in adherence and follow-up practices were observed. The development of a unified, context-specific national guideline is recommended to strengthen standardization of care and improve patient outcomes in Bangladesh.
- Open Access
The Evolving Landscape of Obesity Research in Bangladesh: A Comprehensive Review
Background Obesity is becoming a serious public health problem in Bangladesh, owing to increased urbanization, economic expansion, and globalization. Sedentary lifestyles, processed diets, gender inequities, and restricted recreational options all contribute to this tendency. Obesity raises the likelihood of chronic illnesses such as diabetes while also putting pressure on healthcare services. This study investigates obesity trends, risk factors, difficulties, and management to inform effective public health policies and interventions in Bangladesh. Methods This study uses secondary data from the 2017-2018 BDHS to estimate obesity prevalence and investigate disparities. It examined trends from 1999 to 2014 and projected them until 2025, with an emphasis on dietary changes, inactivity, and the mental health impact of NCDs. The policy data came from the government and non-governmental organisations. Rural research deficiencies were found. Results Obesity is increasing in Bangladesh. According to BDHS data, 32.67% of men and 45.60% of women are impacted. The urban prevalence rate is 21.7%, whereas the rural rate is 14.3%. From 1999 to 2014, urban women’s obesity increased from 7.47% to 21.23%. Urban rates may reach 25% by 2025. Fast food contains 300-500 calories each meal. Since 2010, vegetable consumption has declined by 20-30%. Obesity affects both high (35%) and low-SES (15-20%) populations. NCDs afflict 40% of obese individuals, and diabetes will rise to 14% by 2025. Mental health difficulties affect 25-30% of obese women. Policies such as SSB taxes are restricted, and rural research is sparse (10-15% of studies). Conclusion Obesity is increasing in Bangladesh as a result of urbanization, poor diet, and inactivity, particularly among women and urban populations. NCDs and mental health problems are significant consequences. Policies lack scope and enforcement, with rural regions being disregarded. Nationwide data, customized programs, and tougher restrictions are required, with an emphasis on the relationship between childhood obesity and NCDs. More research and legislative action can assist to control the pandemic.
Open AccessThe Evolving Landscape of Obesity Research in Bangladesh: A Comprehensive Review
Background Obesity is becoming a serious public health problem in Bangladesh, owing to increased urbanization, economic expansion, and globalization. Sedentary lifestyles, processed diets, gender inequities, and restricted recreational options all contribute to this tendency. Obesity raises the likelihood of chronic illnesses such as diabetes while also putting pressure on healthcare services. This study investigates obesity trends, risk factors, difficulties, and management to inform effective public health policies and interventions in Bangladesh. Methods This study uses secondary data from the 2017-2018 BDHS to estimate obesity prevalence and investigate disparities. It examined trends from 1999 to 2014 and projected them until 2025, with an emphasis on dietary changes, inactivity, and the mental health impact of NCDs. The policy data came from the government and non-governmental organisations. Rural research deficiencies were found. Results Obesity is increasing in Bangladesh. According to BDHS data, 32.67% of men and 45.60% of women are impacted. The urban prevalence rate is 21.7%, whereas the rural rate is 14.3%. From 1999 to 2014, urban women’s obesity increased from 7.47% to 21.23%. Urban rates may reach 25% by 2025. Fast food contains 300-500 calories each meal. Since 2010, vegetable consumption has declined by 20-30%. Obesity affects both high (35%) and low-SES (15-20%) populations. NCDs afflict 40% of obese individuals, and diabetes will rise to 14% by 2025. Mental health difficulties affect 25-30% of obese women. Policies such as SSB taxes are restricted, and rural research is sparse (10-15% of studies). Conclusion Obesity is increasing in Bangladesh as a result of urbanization, poor diet, and inactivity, particularly among women and urban populations. NCDs and mental health problems are significant consequences. Policies lack scope and enforcement, with rural regions being disregarded. Nationwide data, customized programs, and tougher restrictions are required, with an emphasis on the relationship between childhood obesity and NCDs. More research and legislative action can assist to control the pandemic.
- Open Access
- 6 April 2025
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 25, 200399
Cardiovascular risk in newly diagnosed patients with type 2 diabetes mellitus: a nationwide, facility-based, cross-sectional study in Bangladesh
- 6 April 2025
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 25, 200399
Open AccessCardiovascular risk in newly diagnosed patients with type 2 diabetes mellitus: a nationwide, facility-based, cross-sectional study in Bangladesh
- Open Access
- 30 May 2024
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Diabetes Endocrinology and Metabolism
- Vol. 15 (1) , 11-16
Thyroid Function Status and Its Impact on Feto-maternal Outcome in Pregnant Women in Bangladesh: A Hospital-based Cross-sectional Study
Background: Thyroid disorders are common in pregnancy and are associated with adverse pregnancy outcomes. The objective of the present study was to assess thyroid status and its association with adverse maternal and neonatal outcomes in pregnant women in Bangladesh.Methods: This cross-sectional study was conducted on 252 women with term pregnancy included from the Department of Gynecology and Obstetrics of Bangabandhu Sheikh Mujib Medical University (BSMMU) Hospital from September 2019 to October 2020. Their baseline information was collected by face-to-face interviews using a semi-structured questionnaire and approximately 3 ml of blood was drawn after maintaining all aseptic precautions for FT4, TSH, and anti-thyroid antibody (anti-TPO-Ab and anti-TG-Ab) estimation. All laboratory procedures were performed using an autoanalyzer (ADVIA Centaur CP, manufactured by Siemens Healthcare Diagnostic Inc., USA). To assess the thyroid function status of the newborn, blood was drawn by the heel-prick technique, and TSH was analyzed using the same autoanalyzer.Results: The mean gestational age of the pregnant women was 38.3 (SD 1.3) weeks. Their mean FT4 and TSH levels were 0.96 (SD 0.1) ng/dL (reference range 0.87–1.54 ng/dL for pregnant women) and 1.8 (SD 1.6) mIU/ml (reference range 0.3-3 mIU/L for pregnant women), respectively. The prevalence of overt hypothyroidism was 3.2%, and subclinical hypothyroidism was 5.2%. None of the pregnant women were diagnosed with overt or subclinical hyperthyroidism. All the women with overt hypothyroidism and almost half of the patients with subclinical hypothyroidism had a positive anti-thyroid antibody status (overall prevalence of positive anti-thyroid antibody was 13%). Adverse maternal and fetal outcomes, such as postpartum hemorrhage, low birth weight, intrauterine growth retardation and neonatal hypothyroidism, were more prevalent among women with overt or subclinical hypothyroidism (p value <0.001).Conclusion: A substantial number of pregnant women in Bangladesh suffer from subclinical or overt hypothyroidism, which increases their risk of adverse pregnancy outcomes.
- 30 May 2024
- Published by Sri Lanka Journals Online in Sri Lanka Journal of Diabetes Endocrinology and Metabolism
- Vol. 15 (1) , 11-16
Open AccessThyroid Function Status and Its Impact on Feto-maternal Outcome in Pregnant Women in Bangladesh: A Hospital-based Cross-sectional Study
Background: Thyroid disorders are common in pregnancy and are associated with adverse pregnancy outcomes. The objective of the present study was to assess thyroid status and its association with adverse maternal and neonatal outcomes in pregnant women in Bangladesh.Methods: This cross-sectional study was conducted on 252 women with term pregnancy included from the Department of Gynecology and Obstetrics of Bangabandhu Sheikh Mujib Medical University (BSMMU) Hospital from September 2019 to October 2020. Their baseline information was collected by face-to-face interviews using a semi-structured questionnaire and approximately 3 ml of blood was drawn after maintaining all aseptic precautions for FT4, TSH, and anti-thyroid antibody (anti-TPO-Ab and anti-TG-Ab) estimation. All laboratory procedures were performed using an autoanalyzer (ADVIA Centaur CP, manufactured by Siemens Healthcare Diagnostic Inc., USA). To assess the thyroid function status of the newborn, blood was drawn by the heel-prick technique, and TSH was analyzed using the same autoanalyzer.Results: The mean gestational age of the pregnant women was 38.3 (SD 1.3) weeks. Their mean FT4 and TSH levels were 0.96 (SD 0.1) ng/dL (reference range 0.87–1.54 ng/dL for pregnant women) and 1.8 (SD 1.6) mIU/ml (reference range 0.3-3 mIU/L for pregnant women), respectively. The prevalence of overt hypothyroidism was 3.2%, and subclinical hypothyroidism was 5.2%. None of the pregnant women were diagnosed with overt or subclinical hyperthyroidism. All the women with overt hypothyroidism and almost half of the patients with subclinical hypothyroidism had a positive anti-thyroid antibody status (overall prevalence of positive anti-thyroid antibody was 13%). Adverse maternal and fetal outcomes, such as postpartum hemorrhage, low birth weight, intrauterine growth retardation and neonatal hypothyroidism, were more prevalent among women with overt or subclinical hypothyroidism (p value <0.001).Conclusion: A substantial number of pregnant women in Bangladesh suffer from subclinical or overt hypothyroidism, which increases their risk of adverse pregnancy outcomes.
- Open Access
- 5 December 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-9
Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study
Background: Achievement of lipid targets is crucial in patients with type 2 diabetes mellitus (T2DM) to mitigate the risk of cardiovascular diseases (CVD). Data on lipid-control status among patients with T2DM in Bangladesh are scarce. This study was conducted to determine the lipid-control status among patients with T2DM who were on lipid-lowering drugs in the country. Methods: This cross-sectional study was conducted in the diabetes outpatient departments of several tertiary hospitals in Bangladesh from January 2022 to December 2022. Adults of both sexes diagnosed with T2DM for at least one year and were on the lipid-lowering drug(s) for a minimum of 3 months were included in the study by consecutive sampling. Patients’ data were collected by face-to-face interviews, and blood samples were collected for fasting lipid profile. The lipid target was set at < 200 mg/dL for total cholesterol (TC), < 150 mg/dL for triglyceride (TG), < 100 mg/dL for low-density lipoprotein cholesterol (LDL-C), > 40 mg/dL for high-density lipoprotein cholesterol (HDL-C), and < 160 mg/dL for non-HDL cholesterol (non-HDL-C). Result: Three thousand sixty patients (age 44.7 ± 13.3 years, female 57%) with T2DM were evaluated. Overall, almost 81% of the study subjects achieved the LDL-C target. Besides, TC, TG, HDL-C, and non-HDL-C targets were achieved by 40.8, 21.6, 66.3, and 44.1% of patients, respectively. However, all the lipid parameters were under control in only 8.8% of patients. Almost 77.6% of the patients with ischemic heart disease, 81.5% of patients with stroke, and 65% of patients with CKD had LDL levels < 70 mg/dL. Only 10.03% achieved the HbA1c target of < 7%. 7.4% of patients achieved both HbA1c < 7% and LDL < 100 mg/dL and 5% achieved both HbA1c < 7% and LDL < 70 mg/dL. Advanced age (aOR 0.97, 95% CI 0.96, 0.98, p < 0.001), longstanding T2DM (aOR 0.53, 95% CI 0.39, 0.72, p < 0.001), and non-statin therapy (aOR 0.25, 95% CI 0.16, 0.37, p < 0.001) were negatively associated with lipid control (LDL < 100 mg/dL) while using oral hypoglycemic drugs or insulin (aOR 2.01, 95% CI 1.45, 2.77, p < 0.001) and having cardiovascular comorbidity (aOR 3.92, 95% CI 3.00, 5.12, p < 0.001) were positively associated with lipid control. Conclusion: Though most patients with T2DM achieved their target LDL level, the prevalence of both glycemic and overall lipid control was low in our study despite lipid-lowering therapy.
- 5 December 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-9
Open AccessStatus of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study
Background: Achievement of lipid targets is crucial in patients with type 2 diabetes mellitus (T2DM) to mitigate the risk of cardiovascular diseases (CVD). Data on lipid-control status among patients with T2DM in Bangladesh are scarce. This study was conducted to determine the lipid-control status among patients with T2DM who were on lipid-lowering drugs in the country. Methods: This cross-sectional study was conducted in the diabetes outpatient departments of several tertiary hospitals in Bangladesh from January 2022 to December 2022. Adults of both sexes diagnosed with T2DM for at least one year and were on the lipid-lowering drug(s) for a minimum of 3 months were included in the study by consecutive sampling. Patients’ data were collected by face-to-face interviews, and blood samples were collected for fasting lipid profile. The lipid target was set at < 200 mg/dL for total cholesterol (TC), < 150 mg/dL for triglyceride (TG), < 100 mg/dL for low-density lipoprotein cholesterol (LDL-C), > 40 mg/dL for high-density lipoprotein cholesterol (HDL-C), and < 160 mg/dL for non-HDL cholesterol (non-HDL-C). Result: Three thousand sixty patients (age 44.7 ± 13.3 years, female 57%) with T2DM were evaluated. Overall, almost 81% of the study subjects achieved the LDL-C target. Besides, TC, TG, HDL-C, and non-HDL-C targets were achieved by 40.8, 21.6, 66.3, and 44.1% of patients, respectively. However, all the lipid parameters were under control in only 8.8% of patients. Almost 77.6% of the patients with ischemic heart disease, 81.5% of patients with stroke, and 65% of patients with CKD had LDL levels < 70 mg/dL. Only 10.03% achieved the HbA1c target of < 7%. 7.4% of patients achieved both HbA1c < 7% and LDL < 100 mg/dL and 5% achieved both HbA1c < 7% and LDL < 70 mg/dL. Advanced age (aOR 0.97, 95% CI 0.96, 0.98, p < 0.001), longstanding T2DM (aOR 0.53, 95% CI 0.39, 0.72, p < 0.001), and non-statin therapy (aOR 0.25, 95% CI 0.16, 0.37, p < 0.001) were negatively associated with lipid control (LDL < 100 mg/dL) while using oral hypoglycemic drugs or insulin (aOR 2.01, 95% CI 1.45, 2.77, p < 0.001) and having cardiovascular comorbidity (aOR 3.92, 95% CI 3.00, 5.12, p < 0.001) were positively associated with lipid control. Conclusion: Though most patients with T2DM achieved their target LDL level, the prevalence of both glycemic and overall lipid control was low in our study despite lipid-lowering therapy.
- Open Access
- 26 June 2023
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 15 (1) , 1-9
Comparison of fasting and random lipid profiles among subjects with type 2 diabetes mellitus: an outpatient-based cross-sectional study in Bangladesh
Background: Despite the wide acceptability of fasting lipid profiles in practice, emerging evidence suggests that random lipid profiles might be a convenient alternative for lipid measurement. The objective of the present study was to compare the fasting and random lipid profile among subjects with type 2 diabetes mellitus (T2DM). Methods: The present cross-sectional study included 1543 subjects with T2DM visiting several endocrinology outpatient clinics throughout Bangladesh from January to December 2021. The fasting lipid profile was measured in the morning following 8–10 h of overnight fasting, and the random lipid profile was measured at any time of the day, irrespective of the last meal. The values of fasting and random lipids were compared using the Wilcoxon signed-rank test and Spearman rank correlation coefficients. Results: In this study, a good level of correlation was observed between fasting and random lipid levels [r = 0.793, p < 0.001 for triglyceride (TG); r = 0.873, p < 0.001 for low-density lipoprotein cholesterol (LDL-C); r = 0.609, p < 0.001 for high-density lipoprotein cholesterol (HDL-C); and r = 0.780, p < 0.001 for total cholesterol (TC)]. In addition, TG and TC levels increased by 14% and 0.51%, respectively, in the random state compared to the fasting state (p- <0.05), while LDL-C levels decreased by 0.71% (p-value 0.42). No change was noticed in the HDL-C level. The difference between fasting and random lipid profiles was similar irrespective of patients’ age, sex, BMI, glucose-lowering drug(s), and lipid-lowering therapy. Conclusions: Random lipid profile correlates significantly with fasting lipid profile with little difference. Hence, it might be a reliable alternative for fasting lipid profile in patients with T2DM.
- 26 June 2023
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 15 (1) , 1-9
Open AccessComparison of fasting and random lipid profiles among subjects with type 2 diabetes mellitus: an outpatient-based cross-sectional study in Bangladesh
Background: Despite the wide acceptability of fasting lipid profiles in practice, emerging evidence suggests that random lipid profiles might be a convenient alternative for lipid measurement. The objective of the present study was to compare the fasting and random lipid profile among subjects with type 2 diabetes mellitus (T2DM). Methods: The present cross-sectional study included 1543 subjects with T2DM visiting several endocrinology outpatient clinics throughout Bangladesh from January to December 2021. The fasting lipid profile was measured in the morning following 8–10 h of overnight fasting, and the random lipid profile was measured at any time of the day, irrespective of the last meal. The values of fasting and random lipids were compared using the Wilcoxon signed-rank test and Spearman rank correlation coefficients. Results: In this study, a good level of correlation was observed between fasting and random lipid levels [r = 0.793, p < 0.001 for triglyceride (TG); r = 0.873, p < 0.001 for low-density lipoprotein cholesterol (LDL-C); r = 0.609, p < 0.001 for high-density lipoprotein cholesterol (HDL-C); and r = 0.780, p < 0.001 for total cholesterol (TC)]. In addition, TG and TC levels increased by 14% and 0.51%, respectively, in the random state compared to the fasting state (p- <0.05), while LDL-C levels decreased by 0.71% (p-value 0.42). No change was noticed in the HDL-C level. The difference between fasting and random lipid profiles was similar irrespective of patients’ age, sex, BMI, glucose-lowering drug(s), and lipid-lowering therapy. Conclusions: Random lipid profile correlates significantly with fasting lipid profile with little difference. Hence, it might be a reliable alternative for fasting lipid profile in patients with T2DM.
- Open Access
- 30 May 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (5) , e000635
Sexual dysfunction in women with type 2 diabetes mellitus: A single-centre cross-sectional study from Bangladesh
Objective: Sexual dysfunction among women with diabetes is a common but neglected health issue worldwide. The objective of the present study was to investigate the prevalence of sexual dysfunction and its associated factors among women with type 2 diabetes mellitus (T2DM). Subjects and methods: This cross-sectional comparative study comprises 150 women with diabetes and 100 healthy women without diabetes who visited the endocrinology outpatient department of Mymensingh Medical College Hospital (MMCH). The data were collected from July to December [...] ABSTRACT Objective: Sexual dysfunction among women with diabetes is a common but neglected health issue worldwide. The objective of the present study was to investigate the prevalence of sexual dysfunction and its associated factors among women with type 2 diabetes mellitus (T2DM). Subjects and methods: This cross-sectional comparative study comprises 150 women with diabetes and 100 healthy women without diabetes who visited the endocrinology outpatient department of Mymensingh Medical College Hospital (MMCH). The data were collected from July to December
- 30 May 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (5) , e000635
Open AccessSexual dysfunction in women with type 2 diabetes mellitus: A single-centre cross-sectional study from Bangladesh
Objective: Sexual dysfunction among women with diabetes is a common but neglected health issue worldwide. The objective of the present study was to investigate the prevalence of sexual dysfunction and its associated factors among women with type 2 diabetes mellitus (T2DM). Subjects and methods: This cross-sectional comparative study comprises 150 women with diabetes and 100 healthy women without diabetes who visited the endocrinology outpatient department of Mymensingh Medical College Hospital (MMCH). The data were collected from July to December [...] ABSTRACT Objective: Sexual dysfunction among women with diabetes is a common but neglected health issue worldwide. The objective of the present study was to investigate the prevalence of sexual dysfunction and its associated factors among women with type 2 diabetes mellitus (T2DM). Subjects and methods: This cross-sectional comparative study comprises 150 women with diabetes and 100 healthy women without diabetes who visited the endocrinology outpatient department of Mymensingh Medical College Hospital (MMCH). The data were collected from July to December
- Open Access
- 18 April 2023
- Published by Bangladesh Academy of Sciences in Bangabandhu Sheikh Mujib Medical University Journal
- Vol. 16 (1) , 41-57
Fasting with diabetes during Ramadan: An updated review
Introduction: In reality, many Muslims have an intense spiritual urge to participate in fasting, even those who could get an exemption. There are many cultural variations in the Muslim population in different parts of the world, even in the same country with different social and family backgrounds. Thus, persons with diabetes should seek medical advice before planning to fast or proceed to fast during Ramadan. Materials: This was a narrative, non-systematic review of the international literature from the major medical online database (PubMed and Google Scholar) in 2023. The term “Ramadan fasting” and “Diabetes” was used to search, and the relevant literature was captured and narrated in a concise thematic account. Results: Practically, there are certain risks associated with fasting for patients with diabetes, which might exacerbate their existing illnesses. Along with the globally increasing prevalence of diabetes, there is an increased number of the population who intend to or fast. The article captured a wide array of topics related to Ramadan fasting by patients with diabetes, including its epidemiology, risk stratification, lifestyle modification, assessment of safety and efficacy profiles of pharmacotherapies, hypo or hyperglycemia, and the impact of diabetes education. Conclusion: Fasting with diabetes poses a range of risks and thus pre-Ramadan risk stratification is essential. Particular attention should focus on the patient’s current risk factors, complications, comorbidities, and the roles of newer antihyperglycemic medicines and advanced technology for safer fasting practices to mitigate the risks of hypoglycemia and or hyperglycemic crises. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(1): 41-57
- 18 April 2023
- Published by Bangladesh Academy of Sciences in Bangabandhu Sheikh Mujib Medical University Journal
- Vol. 16 (1) , 41-57
Open AccessFasting with diabetes during Ramadan: An updated review
Introduction: In reality, many Muslims have an intense spiritual urge to participate in fasting, even those who could get an exemption. There are many cultural variations in the Muslim population in different parts of the world, even in the same country with different social and family backgrounds. Thus, persons with diabetes should seek medical advice before planning to fast or proceed to fast during Ramadan. Materials: This was a narrative, non-systematic review of the international literature from the major medical online database (PubMed and Google Scholar) in 2023. The term “Ramadan fasting” and “Diabetes” was used to search, and the relevant literature was captured and narrated in a concise thematic account. Results: Practically, there are certain risks associated with fasting for patients with diabetes, which might exacerbate their existing illnesses. Along with the globally increasing prevalence of diabetes, there is an increased number of the population who intend to or fast. The article captured a wide array of topics related to Ramadan fasting by patients with diabetes, including its epidemiology, risk stratification, lifestyle modification, assessment of safety and efficacy profiles of pharmacotherapies, hypo or hyperglycemia, and the impact of diabetes education. Conclusion: Fasting with diabetes poses a range of risks and thus pre-Ramadan risk stratification is essential. Particular attention should focus on the patient’s current risk factors, complications, comorbidities, and the roles of newer antihyperglycemic medicines and advanced technology for safer fasting practices to mitigate the risks of hypoglycemia and or hyperglycemic crises. Bangabandhu Sheikh Mujib Medical University Journal 2023;16(1): 41-57
- Open Access
- 22 December 2022
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 15, 4011-4021
Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh
Aim: In Bangladesh, there is a large population of Muslims with type 2 diabetes mellitus (T2DM) who fast during Ramadan. Changes in the pattern of meal and fluid intake during this long-fasting hours may increase the risk of hypoglycaemia, hyperglycaemia, and dehydration. Our key point of focus was to evaluate the efficacy and safety of Empagliflozin, a sodium-glucose co transporter 2 inhibitor (SGLT2i), in patients with T2DM while fasting during Ramadan. Methods: This was a 24-weeks, multi-centre, open-label, two-arm parallel-group study. In this prospective type of observational study, we enrolled patients taking Empagliflozin and Metformin with or without a DPP-4 inhibitor in one group (n = 274) and a parallel group (n = 219) who were treated with Metformin with or without a DPP-4 inhibitor. The primary endpoint of this study was HbA1c reduction, weight loss and the number of reported or symptomatic hypoglycemic events. In secondary endpoints, we evaluated the changes from baseline in blood pressure, estimated glomerular filtration rate (eGFR), serum creatinine, and serum electrolyte, the proportion of volume depletion (≥ 1 event) and incidence of other adverse events (AEs) of interest potentially related to SGLT2 inhibitor. Results: During Ramadan, HbA1c reduction was significant in Empagliflozin arm (− 0.49% vs − 0.12%); [p < 0.001]. From before to the end of the study, significant weight reduction was seen in the Empagliflozin arm (− 1.4 kg vs − 0.09 kg); [p < 0.001]. We observed no significant increase in the incidence of hypoglycemia (0.7% vs 0.4%, p = 0.267) and volume depletion (2.6% vs 1.8%; p = 0.55) in both arm. All these milder forms events did not require any hospital admission. There was no report of serious adverse events or any discontinuation, or reduction of prescribed doses of empagliflozin during Ramadan. Conclusion: Empagliflozin is efficacious and safe for treating adults with T2DM during Ramadan.
- 22 December 2022
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 15, 4011-4021
Open AccessEfficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh
Aim: In Bangladesh, there is a large population of Muslims with type 2 diabetes mellitus (T2DM) who fast during Ramadan. Changes in the pattern of meal and fluid intake during this long-fasting hours may increase the risk of hypoglycaemia, hyperglycaemia, and dehydration. Our key point of focus was to evaluate the efficacy and safety of Empagliflozin, a sodium-glucose co transporter 2 inhibitor (SGLT2i), in patients with T2DM while fasting during Ramadan. Methods: This was a 24-weeks, multi-centre, open-label, two-arm parallel-group study. In this prospective type of observational study, we enrolled patients taking Empagliflozin and Metformin with or without a DPP-4 inhibitor in one group (n = 274) and a parallel group (n = 219) who were treated with Metformin with or without a DPP-4 inhibitor. The primary endpoint of this study was HbA1c reduction, weight loss and the number of reported or symptomatic hypoglycemic events. In secondary endpoints, we evaluated the changes from baseline in blood pressure, estimated glomerular filtration rate (eGFR), serum creatinine, and serum electrolyte, the proportion of volume depletion (≥ 1 event) and incidence of other adverse events (AEs) of interest potentially related to SGLT2 inhibitor. Results: During Ramadan, HbA1c reduction was significant in Empagliflozin arm (− 0.49% vs − 0.12%); [p < 0.001]. From before to the end of the study, significant weight reduction was seen in the Empagliflozin arm (− 1.4 kg vs − 0.09 kg); [p < 0.001]. We observed no significant increase in the incidence of hypoglycemia (0.7% vs 0.4%, p = 0.267) and volume depletion (2.6% vs 1.8%; p = 0.55) in both arm. All these milder forms events did not require any hospital admission. There was no report of serious adverse events or any discontinuation, or reduction of prescribed doses of empagliflozin during Ramadan. Conclusion: Empagliflozin is efficacious and safe for treating adults with T2DM during Ramadan.